| » View all news titles |
» View titles this week |
» View titles this month |
02/15/2018
A chemotherapy resistance mutation commonly seem in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) appears to make leukemic cells vulnerable to targeting with drugs that inhibit an enzyme important for cellular proliferation processes, according to a multicenter study.
